Cover Image
市場調查報告書

心房纖維顫動 (AF) 的預測:主要18市場

Atrial Fibrillation Forecast In 18 Major Markets 2015 -2025

出版商 Black Swan Analysis 商品編碼 342571
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
心房纖維顫動 (AF) 的預測:主要18市場 Atrial Fibrillation Forecast In 18 Major Markets 2015 -2025
出版日期: 2015年10月27日 內容資訊: 英文 72 Pages
簡介

心房纖維顫動 (AF) ,是上室性心律不整的最常見類型。若異常的電力信號送至心房,會引起心房纖維顫動 (AF) 。

本報告提供主要18個市場 (美國、法國、德國、義大利、西班牙、英國、巴西、日本、印度、墨西哥、土耳其、加拿大、澳洲、荷蘭、阿根廷、俄羅斯、中國、韓國) 的心房纖維顫動 (AF) 的按照目前患者數 (性別、年齡世代) 的調查分析、目前盛行率,加上疾病概要、危險因素、疾病診斷與預後、主要的症狀和併發症等系統性資訊。

圖表

簡介

病因

危險因素和預防

疾病診斷

變異:各地區/民族

疾病預後與臨床過程

疾病相關的主要併發症/特徵

定量化患者數的手法

心房纖維顫動 (AF) 的盛行率top line

心房纖維顫動 (AF) 的主要類型和心臟的功能

  • 主要的類型的分類
  • 心房纖維顫動 (AF) 相關的心臟狀態

心房纖維顫動 (AF) 的治療種類

簡稱

相關出版

線上的患者基礎資料庫

以患者為基礎的產品

線上的價格資料和平台

參考文件

附錄

目錄
Product Code: ATFB0011015

Atrial Fibrillation (AF) is the most prevalent type of supraventricular arrhythmia. AF occurs when abnormal electric signals are sent to the atria, which cause them to contract quickly and irregularly. For many patients, the condition is largely asymptomatic, however when symptoms become bothersome and frequent, intervention is required to restore normal rhythm.

This report provides the current prevalent population for AF across 18 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Mexico, Turkey, Canada, Australia, Netherlands, Argentina, Russia, China and South Korea) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the classification and patient treatment options for AF. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of AF have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for AF include:

  • Hypertension
  • CHF/ CAD and other structural cardiac diseases
  • Diabetes
  • Mitral Stenosis / other valvular disorders
  • COPD
  • Stroke
  • Rheumatic Heart Disease

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global AF's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of AF and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on AF's prevalent population.
  • Identify sub-populations within AF which require treatment.
  • Gain an understanding of the specific markets that have the largest number of AF patients.

Coverage

  • U.S.
  • United Kingdom
  • France
  • Germany
  • Italy
  • Spain
  • Japan
  • U.K.
  • China
  • India
  • Turkey
  • Canada
  • Australia
  • Netherland
  • Argentine
  • Russia
  • Korea
  • Mexico

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Co-morbid Conditions/ Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
    • Additional data available on request
  • Top-Line Prevalence for Atrial Fibrillation
  • Main Type and Cardiac Features of AF
    • AF Main Type Classification
    • Associated Cardiac Conditions of AF
  • Type of AF Treatment
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Figures:

  • AF prevalence rates for 2015
  • ESC Guidelines for Management of AF

List of Tables

  • Prevalence of AF, total (000s)
  • Prevalence of AF, males (000s)
  • Prevalence of AF, females (000s)
  • Classification of AF by duration of episode, total (000s)
  • Type of AF classified by valvular or non-valvular, total (000s)
  • AF by 5 year incidence of stroke event, total (000s)
  • AF classified by type of ischaemic stroke mechanism, total (000s)
  • Prevalence of hypertension in AF patients, total (000s)
  • Prevalence of CAD in AF patients, total (000s)
  • Prevalence of valvular heart disease in AF patients, total (000s)
  • Prevalence of left ventricular hypertrophy in AF patients, total (000s)
  • AF patients taking anti-arrhythmic drugs, total (000s)
  • AF patients taking Vitamin K antagonists, total (000s)
  • AF patients taking anti-platelet therapy, total (000s)
  • AF patients with a pacemaker/ ICD implant, total (000s)
  • Catheter ablation in AF patients, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of AF by 5-yr age cohort, males (000s)
  • USA Prevalence of AF by 5-yr age cohort, females (000s)
  • France Prevalence of AF by 5-yr age cohort, males (000s)
  • France Prevalence of AF by 5-yr age cohort, females (000s)
  • Germany Prevalence of AF by 5-yr age cohort, males (000s)
  • Germany Prevalence of AF by 5-yr age cohort, females (000s)
  • Italy Prevalence of AF by 5-yr age cohort, males (000s)
  • Italy Prevalence of AF by 5-yr age cohort, females (000s)
  • Spain Prevalence of AF by 5-yr age cohort, males (000s)
  • Spain Prevalence of AF by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of AF by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of AF by 5-yr age cohort, females (000s)
  • Brazil Prevalence of AF by 5-yr age cohort, males (000s)
  • Brazil Prevalence of AF by 5-yr age cohort, females (000s)
  • Japan Prevalence of AF by 5-yr age cohort, males (000s)
  • Japan Prevalence of AF by 5-yr age cohort, females (000s)
  • India Prevalence of AF by 5-yr age cohort, males (000s)
  • India Prevalence of AF by 5-yr age cohort, females (000s)
  • Mexico Prevalence of AF by 5-yr age cohort, males (000s)
  • Mexico Prevalence of AF by 5-yr age cohort, females (000s)
  • Turkey Prevalence of AF by 5-yr age cohort, males (000s)
  • Turkey Prevalence of AF by 5-yr age cohort, females (000s)
  • Canada Prevalence of AF by 5-yr age cohort, males (000s)
  • Canada Prevalence of AF by 5-yr age cohort, females (000s)
  • Australia Prevalence of AF by 5-yr age cohort, males (000s)
  • Australia Prevalence of AF by 5-yr age cohort, females (000s)
  • Netherlands Prevalence of AF by 5-yr age cohort, males (000s)
  • Netherlands Prevalence of AF by 5-yr age cohort, females (000s)
  • Argentina Prevalence of AF by 5-yr age cohort, males (000s)
  • Argentina Prevalence of AF by 5-yr age cohort, females (000s)
  • Russia Prevalence of AF by 5-yr age cohort, males (000s)
  • Russia Prevalence of AF by 5-yr age cohort, females (000s)
  • China Prevalence of AF by 5-yr age cohort, males (000s)
  • China Prevalence of AF by 5-yr age cohort, females (000s)
  • South Korea Prevalence of AF by 5-yr age cohort, males (000s)
  • South Korea Prevalence of AF by 5-yr age cohort, females (000s)
Back to Top